The CDC's Advisory Committee on Immunization Practices (ACIP) postponed a planned vote on changing the universal birth dose recommendation for hepatitis B after deliberations devolved into confusion. Panel members struggled to interpret competing options: retain the universal birth dose, eliminate it, or make it optional for infants of HBsAg‑negative mothers. Multiple ACIP members complained about rapidly changing ballot language and inadequate preparation; outside experts including Helen Chu criticized the meeting's presentation and lack of clarity. The delay forces the CDC to reconcile technical voting language and public comments before a final recommendation can be issued. ACIP advises the CDC on vaccine policy; any change to the birth‑dose guidance would affect newborn immunization schedules nationwide and carry implications for hepatitis B prevention strategies.